chr3:172505508:> Detail (hg38)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr3:172,223,298-172,241,265 |
| hg38 | chr3:172,505,508-172,523,475 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
| Score | Disease name | Description | Source | Pubmed | Links |
|---|---|---|---|---|---|
| 0.001 | squamous cell carcinoma | Antitumor effect of TRAIL on oral squamous cell carcinoma using magnetic nanopar... | BeFree | 24563116 | Detail |
| 0.001 | squamous cell carcinoma | Licochalcone-A induces intrinsic and extrinsic apoptosis via ERK1/2 and p38 phos... | BeFree | 25572524 | Detail |
| <0.001 | Carcinoma, Transitional Cell | NA | BeFree | Detail | |
| 0.003 | Cardiomyopathy, Dilated | NA | LHGDN | Detail | |
| <0.001 | Cardiovascular Diseases | NA | BeFree | Detail | |
| <0.001 | brain ischemia | As ischemic preconditioning reduces inflammatory response to brain ischemia and ... | BeFree | 25032854 | Detail |
| <0.001 | Malignant tumor of cervix | NA | BeFree | Detail | |
| <0.001 | Primary biliary cirrhosis | NA | BeFree | Detail | |
| <0.001 | chondrosarcoma | NA | BeFree | Detail | |
| <0.001 | Churg-Strauss syndrome | NA | BeFree | Detail | |
| <0.001 | colitis | NA | BeFree | Detail | |
| <0.001 | ulcerative colitis | Association of ulcerative colitis with TNF-related apoptosis inducing ligand (TR... | BeFree | 25720720 | Detail |
| 0.124 | Colonic Neoplasms | NA | BeFree,CTD_human,LHGDN | Detail | |
| 0.005 | colorectal carcinoma | EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistanc... | BeFree | 25198428 | Detail |
| 0.005 | colorectal carcinoma | Moreover, treatment of CRC cells with TRAIL or ABT‑737 induces a release of endo... | BeFree | 25434832 | Detail |
| 0.005 | colorectal carcinoma | We provide a clinical rationale that combining HSP90 inhibitor with TRAIL enhanc... | BeFree | 25446253 | Detail |
| 0.123 | Colorectal Neoplasms | NA | BeFree,CTD_human,LHGDN | Detail | |
| <0.001 | adenoid cystic carcinoma | NA | BeFree | Detail | |
| 0.011 | Cessation of life | NA | LHGDN | Detail | |
| 0.006 | Dengue Fever | NA | BeFree,LHGDN | Detail | |
| 0.001 | Diabetes | TRAIL modulates the immune system and protects against the development of diabet... | BeFree | 25759846 | Detail |
| 0.001 | diabetes mellitus | TRAIL modulates the immune system and protects against the development of diabet... | BeFree | 25759846 | Detail |
| 0.001 | diabetes mellitus | Moreover, since an increasing amount of data has indicated the important biologi... | BeFree | 25834817 | Detail |
| 0.080 | Diabetes Mellitus, Experimental | NA | RGD | Detail | |
| 0.001 | Diabetes Mellitus, Insulin-Dependent | NA | BeFree | Detail | |
| 0.003 | Diabetes Mellitus, Non-Insulin-Dependent | NA | BeFree,LHGDN | Detail | |
| 0.003 | Diabetic Nephropathy | NA | BeFree,LHGDN | Detail | |
| 0.003 | Down syndrome | NA | LHGDN | Detail | |
| <0.001 | Experimental Autoimmune Encephalomyelitis | NA | BeFree | Detail | |
| 0.123 | Endometrial Neoplasms | NA | CTD_human,LHGDN | Detail | |
| <0.001 | endometriosis | NA | BeFree | Detail | |
| <0.001 | Esophageal Neoplasms | NA | BeFree | Detail | |
| <0.001 | Fanconi anemia | NA | BeFree | Detail | |
| <0.001 | fibrosarcoma | NA | BeFree | Detail | |
| 0.123 | glioblastoma | The sensitizing effects of PARP inhibition on TRAIL-mediated apoptosis and poten... | BeFree,CTD_human | 25531448 | Detail |
| 0.143 | Glioma | NA | BeFree,CTD_human,LHGDN | Detail | |
| <0.001 | Graft-vs-Host Disease | NA | BeFree | Detail | |
| 0.002 | Head and Neck Neoplasms | NA | GAD | Detail | |
| <0.001 | Severe Dengue | NA | BeFree | Detail | |
| <0.001 | hepatitis | NA | BeFree | Detail | |
| <0.001 | hepatitis A | NA | BeFree | Detail | |
| 0.001 | hepatitis B | NA | BeFree | Detail | |
| 0.003 | Hepatitis, Chronic | NA | LHGDN | Detail | |
| 0.004 | hepatitis C | TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by h... | BeFree,LHGDN | 24927176 | Detail |
| 0.004 | hepatitis C | We demonstrated a marked polarization of NK cells toward cytotoxicity in respons... | BeFree,LHGDN | 26034208 | Detail |
| <0.001 | Herpes Simplex Infections | In addition to type I interferons, TRAIL and granzyme B contributed to the inhib... | BeFree | 26194553 | Detail |
| 0.008 | HIV Infections | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | Hypercholesterolemia, Familial | NA | BeFree | Detail | |
| <0.001 | hyperglycemia | NA | BeFree | Detail | |
| <0.001 | hyperinsulinism | NA | BeFree | Detail | |
| 0.003 | Hyperplasia | NA | LHGDN | Detail | |
| <0.001 | Immunologic Deficiency Syndromes | NA | BeFree | Detail | |
| 0.005 | Inflammation | NA | LHGDN | Detail | |
| 0.123 | influenza | NA | BeFree,CTD_human,LHGDN | Detail | |
| <0.001 | actinic keratosis | NA | BeFree | Detail | |
| 0.120 | Kidney Neoplasm | NA | CTD_human | Detail | |
| 0.128 | leukemia | The present study was designed to explore the effects of low-toxicity Embelin on... | BeFree,CTD_human,LHGDN | 25293521 | Detail |
| 0.008 | chronic lymphocytic leukemia | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | Acute lymphocytic leukemia | NA | BeFree | Detail | |
| <0.001 | Leukemia, Lymphocytic, Acute, L1 | NA | BeFree | Detail | |
| 0.122 | Leukemia, Myelocytic, Acute | NA | BeFree,CTD_human | Detail | |
| <0.001 | myeloid leukemia | NA | BeFree | Detail | |
| 0.001 | Myeloid Leukemia, Chronic | NA | BeFree | Detail | |
| <0.001 | acute promyelocytic leukemia | NA | BeFree | Detail | |
| 0.003 | Leukemia, T-Cell | NA | BeFree,LHGDN | Detail | |
| <0.001 | Adult T-Cell Lymphoma/Leukemia | NA | BeFree | Detail | |
| <0.001 | Leukoencephalopathy, Progressive Multifocal | NA | BeFree | Detail | |
| <0.001 | leukopenia | NA | BeFree | Detail | |
| 0.003 | Biliary cirrhosis | NA | LHGDN | Detail | |
| <0.001 | Liver diseases | NA | BeFree | Detail | |
| 0.124 | Liver neoplasms | The purpose of this study was to explore whether Gli2 silencing enhances efficie... | BeFree,CTD_human | 25535898 | Detail |
| 0.006 | Lung Neoplasms | NA | BeFree,LHGDN | Detail | |
| 0.005 | Lupus Erythematosus, Systemic | NA | BeFree,GAD,LHGDN | Detail | |
| 0.005 | lymphoma | NA | BeFree,LHGDN | Detail | |
| <0.001 | Lymphoproliferative Disorders | NA | BeFree | Detail | |
| 0.003 | Waldenstrom Macroglobulinemia | NA | BeFree,GAD | Detail | |
| <0.001 | macular holes | NA | BeFree | Detail | |
| 0.002 | Malignant neoplasm of stomach | To investigate the association of tumor necrosis factor-related apoptosis induci... | BeFree | 24277417 | Detail |
| 0.120 | Mammary Neoplasms, Experimental | NA | CTD_human | Detail | |
| 0.004 | medulloblastoma | NA | BeFree,LHGDN | Detail | |
| 0.016 | melanoma | In addition, experiments in both hepatocellular carcinoma and melanoma-bearing m... | BeFree,LHGDN | 24971746 | Detail |
| 0.003 | meningitis | NA | BeFree,LHGDN | Detail | |
| <0.001 | Mesothelioma | We reasoned that the anti-inflammatory actions of mesenchymal stromal cells (MSC... | BeFree | 25525034 | Detail |
| 0.018 | multiple myeloma | NA | BeFree,GAD,LHGDN | Detail | |
| 0.007 | multiple sclerosis | TNFSF10 was significantly associated with multiple sclerosis. | BeFree,GAD,LHGDN | 24932510 | Detail |
| <0.001 | myositis | NA | BeFree | Detail | |
| 0.124 | Neoplasm Metastasis | Although diametrically opposed roles of TRAIL are reported both as an inducer of... | BeFree,CTD_human | 25037270 | Detail |
| 0.124 | Neoplasm Metastasis | Ruthenium polypyridyl complex inhibits growth and metastasis of breast cancer ce... | BeFree,CTD_human | 25778692 | Detail |
| 0.002 | Neoplasm Recurrence, Local | NA | GAD | Detail | |
| 0.120 | Neoplasms, Experimental | NA | CTD_human | Detail | |
| 0.120 | Pathologic Neovascularization | NA | CTD_human | Detail | |
| 0.003 | nephrosis | NA | LHGDN | Detail | |
| 0.132 | neuroblastoma | NA | BeFree,CTD_human,LHGDN | Detail | |
| <0.001 | neutropenia | NA | BeFree | Detail | |
| 0.003 | Newcastle disease | NA | LHGDN | Detail | |
| 0.080 | Degenerative polyarthritis | NA | RGD | Detail | |
| 0.002 | osteosarcoma | Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma. | BeFree | 25595474 | Detail |
| 0.002 | osteosarcoma | Inhibition of c-FLIP by RNAi enhances sensitivity of the human osteogenic sarcom... | BeFree | 25824746 | Detail |
| 0.005 | ovarian carcinoma | The synergy of AMG655 with Apo2L/TRAIL extended to primary ovarian cancer cells ... | BeFree | 24909167 | Detail |
| 0.120 | Pancreatic Neoplasm | NA | BeFree,CTD_human | Detail | |
| <0.001 | Parasitic Diseases | NA | BeFree | Detail | |
| 0.080 | polycystic ovary syndrome | NA | RGD | Detail | |
| <0.001 | polycythemia vera | NA | BeFree | Detail | |
| <0.001 | Preleukemia | NA | BeFree | Detail | |
| 0.129 | Prostatic Neoplasms | NA | BeFree,CTD_human,LHGDN | Detail | |
| <0.001 | Reoviridae Infections | NA | BeFree | Detail | |
| <0.001 | retinal detachment | NA | BeFree | Detail | |
| <0.001 | systemic scleroderma | NA | BeFree | Detail | |
| <0.001 | Sezary syndrome | NA | BeFree | Detail | |
| 0.003 | ankylosing spondylitis | NA | BeFree,LHGDN | Detail | |
| <0.001 | Cerebrovascular accident | Strategies aimed to repress the death-inducing ligands TRAIL, to antagonize the ... | BeFree | 25032854 | Detail |
| <0.001 | thoracic outlet syndrome | NA | BeFree | Detail | |
| 0.005 | Thyroid Neoplasm | NA | LHGDN | Detail | |
| 0.002 | Virus Diseases | PolyIC transfection and NDV infection upregulate pro-apoptotic gene TRAIL and do... | BeFree | 25950488 | Detail |
| <0.001 | Ichthyosis, X-Linked | NA | BeFree | Detail | |
| <0.001 | B-Cell Lymphomas | NA | BeFree | Detail | |
| 0.003 | Lymphoma, T-Cell, Cutaneous | NA | BeFree,LHGDN | Detail | |
| 0.002 | Neoplasms, Second Primary | NA | GAD | Detail | |
| <0.001 | Meningitis, Bacterial | NA | BeFree | Detail | |
| <0.001 | acute leukemia | NA | BeFree | Detail | |
| 0.003 | Pancreatitis, Chronic | NA | BeFree,LHGDN | Detail | |
| <0.001 | Squamous cell carcinoma of lung | NA | BeFree | Detail | |
| <0.001 | Migraine Disorders | Association between TNFSF10 polymorphism and migraine susceptibility in a Chines... | BeFree | 25712717 | Detail |
| <0.001 | Atrophic condition of skin | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma of lung (disorder) | NA | BeFree | Detail | |
| <0.001 | esophageal carcinoma | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of mouth | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of testis | It can be concluded that TRAIL death receptor expressions in particular are incr... | BeFree | 25173558 | Detail |
| <0.001 | Malignant neoplasm of thorax | NA | BeFree | Detail | |
| <0.001 | Secondary malignant neoplasm of lung | NA | BeFree | Detail | |
| <0.001 | Secondary malignant neoplasm of bone | NA | BeFree | Detail | |
| <0.001 | Corneal pannus | NA | BeFree | Detail | |
| <0.001 | MELAS syndrome | NA | BeFree | Detail | |
| <0.001 | MERRF syndrome | NA | BeFree | Detail | |
| <0.001 | Tumor Progression | NA | BeFree | Detail | |
| <0.001 | Anaplastic carcinoma | NA | BeFree | Detail | |
| <0.001 | Neuroectodermal Tumors | NA | BeFree | Detail | |
| 0.003 | cholangiocarcinoma | NA | BeFree,LHGDN | Detail | |
| <0.001 | uveal melanoma | NA | BeFree | Detail | |
| <0.001 | Lip and oral cavity carcinoma | NA | BeFree | Detail | |
| <0.001 | Malignant ascites | NA | BeFree | Detail | |
| 0.006 | pancreatic carcinoma | DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancrea... | BeFree | 25482930 | Detail |
| 0.006 | pancreatic carcinoma | Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cell... | BeFree | 25684663 | Detail |
| <0.001 | Fibrosis, Liver | NA | BeFree | Detail | |
| 0.006 | Malignant neoplasm of lung | Thus, the combination of TRAIL and NVB can inhibit lung cancer cell growth by af... | BeFree | 25017445 | Detail |
| 0.006 | Malignant neoplasm of lung | A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung can... | BeFree | 26080425 | Detail |
| <0.001 | Neoplasm, Residual | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of colon stage IV | NA | BeFree | Detail | |
| <0.001 | inflammatory breast carcinoma | NA | BeFree | Detail | |
| <0.001 | gastric adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | Metastatic melanoma | NA | BeFree | Detail | |
| <0.001 | Cancer of Head and Neck | NA | BeFree | Detail | |
| 0.002 | Liver and Intrahepatic Biliary Tract Carcinoma | NA | BeFree | Detail | |
| <0.001 | Squamous cell carcinoma of esophagus | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma Of Esophagus | NA | BeFree | Detail | |
| <0.001 | Laryngeal cancer recurrent | NA | BeFree | Detail | |
| 0.002 | Solid tumour | NA | BeFree | Detail | |
| <0.001 | Acute Undifferentiated Leukemia | NA | BeFree | Detail | |
| <0.001 | laryngeal squamous cell carcinoma | Association between laryngeal squamous cell carcinoma and polymorphisms in tumor... | BeFree | 25605161 | Detail |
| <0.001 | cervix carcinoma | NA | BeFree | Detail | |
| <0.001 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma of colon | NA | BeFree | Detail | |
| <0.001 | eosinophilic esophagitis | TNF-related apoptosis-inducing ligand (TRAIL) regulates midline-1, thymic stroma... | BeFree | 25981737 | Detail |
| 0.002 | Malignant neoplasm of liver | NA | BeFree | Detail | |
| <0.001 | intrahepatic cholangiocarcinoma | NA | BeFree | Detail | |
| <0.001 | malignant mesothelioma | NA | BeFree | Detail | |
| 0.005 | Malignant neoplasm of pancreas | DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancrea... | BeFree | 25482930 | Detail |
| 0.005 | Malignant neoplasm of pancreas | Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cell... | BeFree | 25684663 | Detail |
| <0.001 | Disseminated Malignant Neoplasm | Furthermore, RuPOP exhibits the potential to be developed as a metal-based antim... | BeFree | 25778692 | Detail |
| <0.001 | Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site | NA | BeFree | Detail | |
| 0.007 | Malignant neoplasm of prostate | NA | BeFree | Detail | |
| <0.001 | Hematologic Neoplasms | NA | BeFree | Detail | |
| <0.001 | Non-alcoholic Fatty Liver Disease | NA | BeFree | Detail | |
| <0.001 | Muscle damage | NA | BeFree | Detail | |
| <0.001 | endometrial carcinoma | NA | BeFree | Detail | |
| <0.001 | Secondary malignant neoplasm of liver | NA | BeFree | Detail | |
| <0.001 | Malignant tumor of eye | TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic comp... | BeFree | 25834817 | Detail |
| <0.001 | Recurrent tumor | NA | BeFree | Detail | |
| 0.005 | Hepatitis B, Chronic | NA | LHGDN | Detail | |
| <0.001 | Malignant neoplasm of esophagus | NA | BeFree | Detail | |
| 0.001 | Thyroid carcinoma | NA | BeFree | Detail | |
| 0.003 | Ewings sarcoma | NA | BeFree,LHGDN | Detail | |
| 0.004 | Malignant glioma | NA | BeFree | Detail | |
| <0.001 | primary sclerosing cholangitis | NA | BeFree | Detail | |
| 0.002 | Osteosarcoma of bone | Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma. | BeFree | 25595474 | Detail |
| 0.003 | Carcinogenesis | Enforced expression of miR-148a sensitized cells to TRAIL and reduced lung tumor... | BeFree | 26124099 | Detail |
| 0.008 | prostate carcinoma | NA | BeFree | Detail | |
| <0.001 | polycythemia vera | With the use of an in vitro culture system to generate differentiating erythroid... | BeFree | 16384930 | Detail |
| <0.001 | Epithelial ovarian cancer | NA | BeFree | Detail | |
| 0.011 | breast carcinoma | In summary, this is the first demonstration that a dual approach using simultane... | BeFree | 25586349 | Detail |
| 0.007 | Carcinoma of lung | Thus, the combination of TRAIL and NVB can inhibit lung cancer cell growth by af... | BeFree | 25017445 | Detail |
| 0.007 | Carcinoma of lung | A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung can... | BeFree | 26080425 | Detail |
| 0.008 | colon carcinoma | Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of... | BeFree | 25113506 | Detail |
| 0.008 | colon carcinoma | Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-arme... | BeFree | 25156145 | Detail |
| 0.008 | colon carcinoma | Evaluation of preventive and therapeutic activity of novel non-steroidal anti-in... | BeFree | 25672292 | Detail |
| 0.003 | stomach carcinoma | To investigate the association of tumor necrosis factor-related apoptosis induci... | BeFree | 24277417 | Detail |
| 0.001 | Carcinoma of bladder | We constructed Arg-Gly-Asp (RGD)-modified oncolytic adenovirus, carrying EGFP or... | BeFree | 25973680 | Detail |
| 0.004 | Central neuroblastoma | NA | BeFree | Detail | |
| 0.001 | Malignant neoplasm of kidney | NA | BeFree | Detail | |
| <0.001 | Hypereosinophilia | NA | BeFree | Detail | |
| <0.001 | Parasitic infection | NA | BeFree | Detail | |
| <0.001 | malignant pleural mesothelioma | NA | BeFree | Detail | |
| <0.001 | Adenoviral infections | NA | BeFree | Detail | |
| <0.001 | Invasive breast carcinoma | NA | BeFree | Detail | |
| <0.001 | Rhabdoid Tumor of the Kidney | NA | BeFree | Detail | |
| <0.001 | Testicular malignant germ cell tumor | It can be concluded that TRAIL death receptor expressions in particular are incr... | BeFree | 25173558 | Detail |
| <0.001 | Philadelphia chromosome positive | NA | BeFree | Detail | |
| <0.001 | breast adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | Chronic graft-versus-host disease | NA | BeFree | Detail | |
| 0.123 | ovarian neoplasm | NA | BeFree,CTD_human,LHGDN | Detail | |
| 0.007 | Malignant neoplasm of ovary | The synergy of AMG655 with Apo2L/TRAIL extended to primary ovarian cancer cells ... | BeFree,GAD | 24909167 | Detail |
| <0.001 | Squamous cell carcinoma of the head and neck | NA | BeFree | Detail | |
| 0.004 | sarcoma | Based on this knowledge, we conceived to use modified MSC to deliver tumor necro... | BeFree,LHGDN | 25420617 | Detail |
| <0.001 | Inflammatory disorder | NA | BeFree | Detail | |
| <0.001 | Classical Hodgkin's Lymphoma | NA | BeFree | Detail | |
| 0.001 | pancreatic ductal adenocarcinoma | These results not only suggest that GSK-3β overexpression and nuclear localizati... | BeFree | 24675460 | Detail |
| 0.001 | pancreatic ductal adenocarcinoma | Cancer cell-restricted genetic ablation of murine TRAIL-R in autochthonous KRAS-... | BeFree | 25843002 | Detail |
| <0.001 | Primary Carcinoma | NA | BeFree | Detail | |
| <0.001 | Sporadic Breast Carcinoma | NA | BeFree | Detail | |
| <0.001 | Squamous Cell Breast Carcinoma | NA | BeFree | Detail | |
| <0.001 | Undifferentiated leukemia | NA | BeFree | Detail | |
| 0.002 | renal carcinoma | NA | BeFree | Detail | |
| <0.001 | Metastatic Carcinoma | NA | BeFree | Detail | |
| <0.001 | Posterior capsule opacification | NA | BeFree | Detail | |
| 0.141 | Mammary Neoplasms | In vitro studies into the role of OPG produced by breast tumor cells have demons... | BeFree,CTD_human,LHGDN | 26054853 | Detail |
| <0.001 | Hepatocarcinogenesis | NA | BeFree | Detail | |
| <0.001 | Primary Glioblastoma | NA | BeFree | Detail | |
| 0.001 | Xenograft Model | Furthermore, treatment with pACTERT-TRAIL delivered by magnetic nanoparticles sh... | BeFree | 24563116 | Detail |
| 0.004 | colorectal cancer | EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistanc... | BeFree | 25198428 | Detail |
| 0.004 | colorectal cancer | Moreover, treatment of CRC cells with TRAIL or ABT‑737 induces a release of endo... | BeFree | 25434832 | Detail |
| 0.004 | colorectal cancer | We provide a clinical rationale that combining HSP90 inhibitor with TRAIL enhanc... | BeFree | 25446253 | Detail |
| 0.001 | Non-Malignant Ascites Adverse Event | NA | BeFree | Detail | |
| <0.001 | Glioblastoma multiforme | NA | BeFree | Detail | |
| <0.001 | tumor vasculature | NA | BeFree | Detail | |
| <0.001 | Non-Neoplastic Disorder | NA | BeFree | Detail | |
| <0.001 | Friedreich ataxia 1 | NA | BeFree | Detail | |
| <0.001 | uterine corpus cancer | NA | BeFree | Detail | |
| 0.004 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | NA | BeFree,LHGDN | Detail | |
| 0.003 | Precursor Cell Lymphoblastic Leukemia Lymphoma | NA | BeFree,LHGDN | Detail | |
| <0.001 | Urothelial Carcinoma | NA | BeFree | Detail | |
| 0.150 | liver carcinoma | TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by h... | BeFree,CTD_human,LHGDN | 24927176 | Detail |
| 0.150 | liver carcinoma | Insights from TRAIL mediated signaling in HCC research are catalyzing new lines ... | BeFree,CTD_human,LHGDN | 25037270 | Detail |
| 0.150 | liver carcinoma | The purpose of this study was to explore whether Gli2 silencing enhances efficie... | BeFree,CTD_human,LHGDN | 25535898 | Detail |
| 0.150 | liver carcinoma | Expression of Bcl-xL, cIAP2, survivin and Raf-1 was downregulated following sile... | BeFree,CTD_human,LHGDN | 25607597 | Detail |
| 0.150 | liver carcinoma | Hence, we conclude that Msi1 is a mediator of TRAIL resistance in HCC cells. | BeFree,CTD_human,LHGDN | 25747387 | Detail |
| <0.001 | Promyelocytic leukemia | NA | BeFree | Detail | |
| <0.001 | Nasopharyngeal carcinoma | NA | BeFree | Detail | |
| <0.001 | Nonalcoholic Steatohepatitis | NA | BeFree | Detail | |
| 0.003 | myelodysplastic syndrome | NA | BeFree,LHGDN | Detail | |
| <0.001 | FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder) | NA | BeFree | Detail | |
| 0.001 | Triple Negative Breast Neoplasms | NA | BeFree | Detail | |
| <0.001 | Intracranial glioma | NA | BeFree | Detail | |
| 0.011 | Infection | NA | LHGDN | Detail | |
| <0.001 | Tumors in animals | NA | BeFree | Detail | |
| 0.120 | Spontaneous abortion | NA | CTD_human | Detail | |
| 0.010 | adenocarcinoma | NA | BeFree,LHGDN | Detail | |
| 0.003 | adenoma | NA | LHGDN | Detail | |
| <0.001 | Adenovirus Infections | These studies, for the first time, show correlations between cholesterol/lipid r... | BeFree | 25605010 | Detail |
| 0.003 | Alzheimer's disease | Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Al... | BeFree,LHGDN | 25472798 | Detail |
| 0.006 | anemia | NA | BeFree,LHGDN | Detail | |
| <0.001 | aplastic anemia | NA | BeFree | Detail | |
| 0.003 | Anoxia | NA | LHGDN | Detail | |
| <0.001 | arteriosclerosis | NA | BeFree | Detail | |
| <0.001 | arthritis | NA | BeFree | Detail | |
| 0.001 | rheumatoid arthritis | NA | BeFree | Detail | |
| <0.001 | asthma | NA | BeFree | Detail | |
| 0.003 | Astrocytoma | NA | BeFree,LHGDN | Detail | |
| 0.004 | atherosclerosis | NA | BeFree,LHGDN | Detail | |
| 0.002 | Autoimmune Diseases | NA | BeFree | Detail | |
| 0.001 | Malignant neoplasm of urinary bladder | We constructed Arg-Gly-Asp (RGD)-modified oncolytic adenovirus, carrying EGFP or... | BeFree | 25973680 | Detail |
| 0.003 | Bladder Neoplasm | NA | BeFree,LHGDN | Detail | |
| <0.001 | Bone Diseases | NA | BeFree | Detail | |
| <0.001 | Bone neoplasms | NA | BeFree | Detail | |
| 0.001 | Brain Neoplasms | NA | BeFree | Detail | |
| 0.014 | Malignant neoplasm of breast | In summary, this is the first demonstration that a dual approach using simultane... | BeFree,GAD | 25586349 | Detail |
| <0.001 | Burkitt lymphoma | NA | BeFree | Detail | |
| 0.007 | Malignant tumor of colon | Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of... | BeFree | 25113506 | Detail |
| 0.007 | Malignant tumor of colon | Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-arme... | BeFree | 25156145 | Detail |
| 0.007 | Malignant tumor of colon | Evaluation of preventive and therapeutic activity of novel non-steroidal anti-in... | BeFree | 25672292 | Detail |
| <0.001 | Malignant neoplasm of endometrium | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma of prostate | NA | BeFree | Detail | |
| 0.001 | Malignant neoplasm of thyroid | NA | BeFree | Detail | |
| 0.005 | Non-small cell lung carcinoma | TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and... | BeFree | 25017445 | Detail |
| 0.005 | Non-small cell lung carcinoma | Cancer cell-restricted genetic ablation of murine TRAIL-R in autochthonous KRAS-... | BeFree | 25843002 | Detail |
| 0.005 | Non-small cell lung carcinoma | MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSC... | BeFree | 26124099 | Detail |
| 0.123 | renal cell carcinoma | NA | BeFree,CTD_human | Detail |
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Antitumor effect of TRAIL on oral squamous cell carcinoma using magnetic nanoparticle-mediated gene ... | DisGeNET | Detail |
| Licochalcone-A induces intrinsic and extrinsic apoptosis via ERK1/2 and p38 phosphorylation-mediated... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| As ischemic preconditioning reduces inflammatory response to brain ischemia and ameliorates brain da... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Association of ulcerative colitis with TNF-related apoptosis inducing ligand (TRAIL) gene polymorphi... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant col... | DisGeNET | Detail |
| Moreover, treatment of CRC cells with TRAIL or ABT‑737 induces a release of endogenous HMGB1 into th... | DisGeNET | Detail |
| We provide a clinical rationale that combining HSP90 inhibitor with TRAIL enhances therapeutic effic... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TRAIL modulates the immune system and protects against the development of diabetes. | DisGeNET | Detail |
| TRAIL modulates the immune system and protects against the development of diabetes. | DisGeNET | Detail |
| Moreover, since an increasing amount of data has indicated the important biological activities of th... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The sensitizing effects of PARP inhibition on TRAIL-mediated apoptosis and potential toxicity were a... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus inf... | DisGeNET | Detail |
| We demonstrated a marked polarization of NK cells toward cytotoxicity in response to IFN-α stimulati... | DisGeNET | Detail |
| In addition to type I interferons, TRAIL and granzyme B contributed to the inhibitory effect of HSV-... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The present study was designed to explore the effects of low-toxicity Embelin on TRAIL-induced apopt... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The purpose of this study was to explore whether Gli2 silencing enhances efficiency of TRAIL for hep... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| To investigate the association of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) ge... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In addition, experiments in both hepatocellular carcinoma and melanoma-bearing mice demonstrated tha... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| We reasoned that the anti-inflammatory actions of mesenchymal stromal cells (MSCs) and further antit... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TNFSF10 was significantly associated with multiple sclerosis. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Although diametrically opposed roles of TRAIL are reported both as an inducer of apoptosis and regul... | DisGeNET | Detail |
| Ruthenium polypyridyl complex inhibits growth and metastasis of breast cancer cells by suppressing F... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma. | DisGeNET | Detail |
| Inhibition of c-FLIP by RNAi enhances sensitivity of the human osteogenic sarcoma cell line U2OS to ... | DisGeNET | Detail |
| The synergy of AMG655 with Apo2L/TRAIL extended to primary ovarian cancer cells and was further enha... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Strategies aimed to repress the death-inducing ligands TRAIL, to antagonize the death receptors, or ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| PolyIC transfection and NDV infection upregulate pro-apoptotic gene TRAIL and downregulate the anti-... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Association between TNFSF10 polymorphism and migraine susceptibility in a Chinese population. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| It can be concluded that TRAIL death receptor expressions in particular are increased in testicular ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. | DisGeNET | Detail |
| Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inh... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Thus, the combination of TRAIL and NVB can inhibit lung cancer cell growth by affecting the level of... | DisGeNET | Detail |
| A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor rel... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TNF-related apoptosis-inducing ligand (TRAIL) regulates midline-1, thymic stromal lymphopoietin, inf... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. | DisGeNET | Detail |
| Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inh... | DisGeNET | Detail |
| Furthermore, RuPOP exhibits the potential to be developed as a metal-based antimetastatic agent and ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma. | DisGeNET | Detail |
| Enforced expression of miR-148a sensitized cells to TRAIL and reduced lung tumorigenesis in vitro an... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| With the use of an in vitro culture system to generate differentiating erythroid cells, we found tha... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In summary, this is the first demonstration that a dual approach using simultaneous overexpression o... | DisGeNET | Detail |
| Thus, the combination of TRAIL and NVB can inhibit lung cancer cell growth by affecting the level of... | DisGeNET | Detail |
| A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. | DisGeNET | Detail |
| Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116... | DisGeNET | Detail |
| Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in comb... | DisGeNET | Detail |
| Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG1... | DisGeNET | Detail |
| To investigate the association of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) ge... | DisGeNET | Detail |
| We constructed Arg-Gly-Asp (RGD)-modified oncolytic adenovirus, carrying EGFP or TNF-related apoptos... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| It can be concluded that TRAIL death receptor expressions in particular are increased in testicular ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The synergy of AMG655 with Apo2L/TRAIL extended to primary ovarian cancer cells and was further enha... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Based on this knowledge, we conceived to use modified MSC to deliver tumor necrosis factor-related a... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| These results not only suggest that GSK-3β overexpression and nuclear localization contribute to TNF... | DisGeNET | Detail |
| Cancer cell-restricted genetic ablation of murine TRAIL-R in autochthonous KRAS-driven models of non... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In vitro studies into the role of OPG produced by breast tumor cells have demonstrated that OPG can ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Furthermore, treatment with pACTERT-TRAIL delivered by magnetic nanoparticles showed a significant c... | DisGeNET | Detail |
| EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant col... | DisGeNET | Detail |
| Moreover, treatment of CRC cells with TRAIL or ABT‑737 induces a release of endogenous HMGB1 into th... | DisGeNET | Detail |
| We provide a clinical rationale that combining HSP90 inhibitor with TRAIL enhances therapeutic effic... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus inf... | DisGeNET | Detail |
| Insights from TRAIL mediated signaling in HCC research are catalyzing new lines of study that should... | DisGeNET | Detail |
| The purpose of this study was to explore whether Gli2 silencing enhances efficiency of TRAIL for hep... | DisGeNET | Detail |
| Expression of Bcl-xL, cIAP2, survivin and Raf-1 was downregulated following silencing of SNAIL, whil... | DisGeNET | Detail |
| Hence, we conclude that Msi1 is a mediator of TRAIL resistance in HCC cells. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| These studies, for the first time, show correlations between cholesterol/lipid rafts, oncolytic aden... | DisGeNET | Detail |
| Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| We constructed Arg-Gly-Asp (RGD)-modified oncolytic adenovirus, carrying EGFP or TNF-related apoptos... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In summary, this is the first demonstration that a dual approach using simultaneous overexpression o... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116... | DisGeNET | Detail |
| Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in comb... | DisGeNET | Detail |
| Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG1... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity ... | DisGeNET | Detail |
| Cancer cell-restricted genetic ablation of murine TRAIL-R in autochthonous KRAS-driven models of non... | DisGeNET | Detail |
| MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- dbSNP
- rs386626619 dbSNP
- Genome
- hg38
- Position
- chr3:172,505,508-172,523,475
- Variant Type
- snv
Genome browser